ArticleNature medicine2011
In vivo imaging of ligand receptor binding with Gaussia luciferase complementation.
Article in Nature medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 69 citations in OpenAlex.
- A high-throughputActa pharmaceutica Sinica. B · 2023Article
- Enhanced mitochondrial fission inhibits triple-negative breast cancer cell migration through an ROS-dependent mechanism.iScience · 2023Article
- Article
- A nanoluciferase biosensor to investigate endogenous chemokine secretion and receptor binding.iScience · 2021Article
- Interrogating Cellular Communication in Cancer with Genetically Encoded Imaging Reporters.Radiology. Imaging cancer · 2020Review
- Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer.Breast cancer research : BCR · 2020Article
- Short-Term Environmental Conditioning Enhances Tumorigenic Potential of Triple-Negative Breast Cancer Cells.Tomography (Ann Arbor, Mich.) · 2019Article
- Molecular Imaging with Reporter Genes: Has Its Promise Been Delivered?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer.Molecular cancer research : MCR · 2019Article
- Small near-infrared photochromic protein for photoacoustic multi-contrast imaging and detection of protein interactions in vivo.Nature communications · 2018Article
- Article
- Functional Isolation of Tumor-Initiating Cells using Microfluidic-Based Migration Identifies Phosphatidylserine Decarboxylase as a Key Regulator.Scientific reports · 2018Article
- Dual Reporter Bioluminescence Imaging with NanoLuc and Firefly Luciferase.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Fluorescence Lifetime Imaging of a Caspase-3 Apoptosis Reporter.Current protocols in cell biology · 2017Article
- New imaging probes to track cell fate: reporter genes in stem cell research.Cellular and molecular life sciences : CMLS · 2017Review
- Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer.Oncotarget · 2016Article
- The Expanding Toolbox of In Vivo Bioluminescent Imaging.Frontiers in oncology · 2016Review
- Dual-Color Luciferase Complementation for Chemokine Receptor Signaling.Methods in enzymology · 2016Article
- Fluorescence Lifetime Imaging of Apoptosis.Tomography (Ann Arbor, Mich.) · 2015Article
- CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.Molecular cancer therapeutics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Studies of ligand-receptor binding and the development of receptor antagonists would benefit greatly from imaging techniques that translate directly from cell-based assays to living animals. We used Gaussia luciferase protein fragment complementation to quantify the binding of chemokine (C-X-C motif) ligand 12 (CXCL12) to chemokine (C-X-C motif) receptor 4 (CXCR4) and CXCR7. Studies established that small-molecule inhibitors of CXCR4 or CXCR7 specifically blocked CXCL12 binding in cell-based assays and revealed differences in kinetics of inhibiting chemokine binding to each receptor. Bioluminescence imaging showed CXCL12-CXCR7 binding in primary and metastatic tumors in a mouse model of breast cancer. We used this imaging technique to quantify drug-mediated inhibition of CXCL12-CXCR4 binding in living mice. We expect this imaging technology to advance research in areas such as ligand-receptor interactions and the development of new therapeutic agents in cell-based assays and small animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.